Recurrent disease after haploidentical hematopoietic stem cell transplantation (HI HSCT) is a significant obstacle to its success, requiring investigations into mechanisms of relapse to further improve outcomes. Acquired uniparental disomy (aUPD) is a known tumor escape mechanism, [1] [2] [3] [4] in which a mitotic recombination event results in the loss of one parental copy of a chromosome or part of a chromosome and the gain of a second copy from the alternate parent. The consequence of this mutation is a loss of heterozygocity in the affected region with preservation of genetic copy number. aUPD potentially contributes to clonal evolution by rendering tumor cells homozygous for a pre-existing oncogenic mutation. 5, 6 After HI HSCT, Vago and colleagues 7, 8 identified the presence of aUPD in the MHC region of chromosome 6p in leukemic cells in a subset of adult patients with recurrent AML using whole-genome single nucleotide polymorphism (SNP) arrays. aUPD in this region (aUPD-6p) resulted in the loss of the unshared haplotype on the leukemic cells circumventing allogenic recognition and rendering donor lymphocyte infusions (DLI) for post-HSCT relapse ineffective. Active disease at HSCT and a diagnosis of AML have been identified as risk factors for the development of aUPD-6p. 9 Evidence that immunological pressure by the donor immune system contributes to the occurrence of post-HSCT aUPD-6p consists of associations between aUPD-6p and specificity to HLA-mismatched HSCT, higher T cell doses in the allogeneic graft, chronic GVHD, 9 treatment with DLI 10 and lateness of relapse implicating immunological as opposed to conditioning failure to control the disease. Information regarding the development of aUPD-6p as a feature of relapse after a cyclophosphamide (CY)-based HI HSCT is limited. Therefore, we investigated whether this mechanism of relapse was prevalent in patients undergoing a two-step HI HSCT using CY tolerization to inform treatment decisions.
Starting at the end of 2011, patients with a diagnosis of AML who relapsed after HI HSCT using the Jefferson two-step approach were to be assessed for aUPD-6p. The two-step approach has been described elsewhere, [11] [12] [13] but briefly after conditioning with 12 Gy total body irradiation (myeloablative) or a fludarabine-based reduced intensity conditioning, patients received a fixed dose of 2 × 10 8 /kg T cells (HSCT step 1) followed 2-days later by CY for bidirectional tolerization. Two days after CY, all patients received a CD34-selected donor product (HSCT step 2). Mycophenolate mofetil and tacrolimus were used as GVHD prophylaxis. The former was discontinued at day +28, a taper of the latter was initiated at day +42 in the absence of active GVHD.
HLA typing of leukemic blood or mononuclear-cell-sorted leukemic marrow was the primary method used to detect the presence or absence of the recipient unshared haplotype in patients with relapsed disease. aUPD-6p was considered likely if the recipient's unshared haplotype was not detected despite the presence of recipient leukemic blasts. HLA typing was performed on isolated DNA using the sequence-specific primer method at low/medium antigen resolution. To ensure that there was an adequate number of malignant cells in the specimens to reliably detect the recipient unshared haplotype if present, an add-back experiment was performed in which isolated DNA from one individual was combined with that from a second, unique phenotype over a range of 40-0.1%. The detection level varied with the specific antigen, with a reliable detection range from 2.5 to 10%. Even at 0.1%, faint bands could be distinguished that could define some of the antigens in the cell phenotypes. In the current analysis, all patients tested for aUPD-6p using HLA typing had at least 10% leukemic cells in the testing sample and therefore, the unshared recipient haplotype, if present, would have been detected.
Leukemic marrow and blood from the time of relapse from the first two patients was sent to LabCorp Genzyme Genetics for whole-genome high-density (HD) chromosome SNP/copy number microarray (MA) analysis in lieu of HLA typing. Beginning in 2015, in-house whole-genome HD SNP MA analysis became available and was performed on stored chimerism samples collected at the time of relapse to correlate the results of HLA typing. SNP MA analysis, based on dilution experiments involving other types of copy-number variants, would be expected to detect aUPD in a sample with at least 30-50% affected cells. All samples undergoing SNP MA analysis contained 440% recipient cells. Table 1 contains sample characteristics. An Institutional Review Boardapproved informed consent allowing analysis and publication of outcome data was obtained for all patients at the time of HSCT in accordance with the Declaration of Helsinki.
Fifty consecutive patients with AML, undergoing a 2-step HI HSCT between 2006 and 2015 (median year of HSCT 2012), who were alive during the monitoring period of 2011-2015 were included in this analysis. Forty-one of 50 (82%) were transplanted prior to 2014. All patients were fully engrafted, were without evidence of AML on day +28 staging studies, and survived until at least day+60. Thirteen of 50 (26%) patients (Table 1) relapsed after HI HSCT with a cumulative incidence of relapse (with non-relapse mortality as a competing event) at 5 years of 39% in patients with active disease versus 20% without active disease at the time of HSCT. The majority of the relapse group had high-risk AML as evidenced by the presence of refractory disease at HSCT, second or greater CR, or high-risk cytogenetic or molecular findings at diagnosis.
One of the 13 patients (patient 8) with a low blast count at relapse was not evaluable for aUPD-6p by HLA typing or SNP MA analysis. The remaining 12 patients were evaluated using HLA typing and SNP MA analysis (n = 9), SNP analysis alone (n = 2) or HLA typing alone (n = 1). In cases where both tests were performed, HLA typing results were concordant with SNP MA findings. aUPD-6p was found in 6/12 patients (50%). The median time to relapse in patients with and without aUPD-6p was 425 (range: 270-1902) versus 180 (range: 63-465) days, respectively.
Two patients, both without evidence of aUPD-6p at relapse by HLA typing and SNP MA analysis, were given salvage treatment with cytarabine and/or azacitidine, interferon alpha and DLI. The first patient (patient 7) died in remission 2 months after DLI of Died without further therapy
Letter to the Editor complications of GVHD. The second patient (patient 9) initially achieved remission but relapsed 2 months later. At post-DLI relapse, the leukemic cells were without evidence of the unshared haplotype, consistent with a new finding of aUPD-6p, later supported by retrospective SNP MA analysis (Figure 1 ). The small number of patients in the relapse group precluded identifying a correlation between immunological pressure in the form of acute or chronic GVHD and the development of aUPD-6p. Prior to relapse, only 3 of the 12 relapsing patients, one in the nonaUPD-6p group and two in the aUPD-6p group, developed acute GVHD, all grade II involving only the skin. Two of the patients in the aUPD-6p group with acute GVHD went on to develop chronic GVHD. No patients in the non-aUPD-6p group developed chronic GVHD.
Interestingly, in contrast to the initial findings by Vago and colleagues, 7 new cytogenetic abnormalities were detected at relapse in the majority of patients both with and without aUPD-6p. Results from the SNP MA were consistent with the cytogenetics and FISH analyses, taking into account the differences in the abnormalities detectable by these different modalities. aUPD in chromosomes 17q and 22, respectively were detected in two patients in the aUPD-6p group only by SNP MA analysis.
Per programme guidelines initiated in the latter half of 2011, patients with AML relapsing after HI HSCT were to be tested for aUPD-6p. The outcomes of 50 patients over 51 months were monitored, and in this time frame, 13 patients (26%) relapsed, with one-half of the relapse group having aUPD-6p as a feature of their disease recurrence. At the time of the current analysis, 82% of the subjects were at least 2 years post-HI HSCT and exhibited relapse rates that were lower than that reported for patients undergoing HLA-matched and HI HSCT at 2 years, 14 suggesting that the development of aUPD-6p was not a major contributor to relapse risk after HI HSCT. The majority of patients who develop aUPD-6p have high risk or resistant disease at HSCT, and in this series, clonal evolution was evident at the time of relapse, whether aUPD-6p was present or not. These factors predict for genomic instability, which as a result of MHC-mismatched allogeneic pressure facilitates the development of subclones with aUPD-6p. Therefore, while HLA mismatched HSCT may provide a pathway of leukemic escape through aUPD-6p, it is unlikely to increase the risk of relapse in and of itself.
Haplotype or antigen loss-associated relapse has been demonstrated after mismatched unrelated donor HSCT 10 as well as in the post-transplant CY setting using marrow as a graft source, and in the absence of DLI and GVHD. 15 Therefore, HLA mismatch appears to be the unifying risk factor for this type of leukemic escape mechanism. The frequency of its occurrence within the relapsed population, however, may be related to the degree of immunological pressure in the forms of GVHD, DLI or the aggressiveness of the HSCT approach. In the current analysis, the 50% rate of aUPD-6p in AML patients with post-HSCT relapse is higher than that reported elsewhere. 8 While immunological pressure in the forms of GVHD and DLI were not prominent features in our series, the two-step regimen utilizes a high dose of T cells, which has been associated with aUPD-6p in one report 9 as well as a rapid taper of post-HSCT GVHD prophylaxis, resulting in early, robust immune reconstitution. In this scenario, prolonged control of the AML is achieved as a result of the aggressiveness of the approach, allowing late mechanisms of relapse such as aUPD-6p to develop.
In this retrospective analysis, it was not possible to assess for HLA loss due to aUPD-6p in leukemic cells prior to HSCT, as has been reported by others. 16, 17 Two of the six patients with post-HI HSCT aUPD-6p underwent HLA typing with high percentages of blasts in the blood at diagnosis and all antigens from both haplotypes were present. Because HLA loss due to aUPD-6p is a relatively uncommon finding prior to HSCT, 17 aUPD-6p most likely developed after HI HSCT in our analyzed group. However, HLA loss At relapse: 46, XY, der(1)t(1; 3), t(1; 6), der(3)t(1; 3), der(6), t (1;6), add(21)(10)/46, XY, t(3; 9), del (11) Letter to the Editor on leukemic cells should be assessed prior to HSCT, if possible, to guide decisions regarding donor selection. The optimal treatment approach for patients with post-HI HSCT relapse is unclear, given that continued immunotherapy such as DLI could further stimulate genetic instability. In the current series, the two most successfully treated patients (Table 1 patients 4 and  6) , both with aUPD-6p, regained morphologic CR after treatment with aggressive AML re-induction regimens. Afterwards, the first patient responded to interleukin-2 therapy for 1 year, presumably exploiting natural killer cell alloreactivity, the branch of the immune system not affected by aUPD-6p. This patient did not have a killer immunoglobulin-like receptor ligand mismatch with his donor before HSCT nor after haplotype loss, suggesting that NK effects were via activating receptors, if they were present. The other patient underwent a second HSCT with an alternate donor targeting the unmutated haplotype and remains in CR 9 months after HSCT. The courses of these two patients support the use of aggressive salvage therapy to treat aUPD-6p associated relapse, , all three haplotypes (unique recipient, unique donor and shared haplotype) are present on HLA typing, indicating that the leukemic cells still express the unique, unshared recipient haplotype, corroborated by SNP MA analysis, which showed the presence of multiple tracks in chromosome 6p (thin arrow), demonstrating heterozygosity. The thick arrow shows an unbroken copy number track, demonstrating a normal gene copy number. After post-relapse treatment (c), HLA typing now shows the absence of the unique recipient haplotype despite the presence of recipient leukemic cells. SNP MA analysis also changes, in that the middle tracks (thin arrow) are absent, signifying the loss of heterozygosity. Despite this loss, copy number is conserved (thick arrow). Taken together, HLA and SNP MA analyses suggest that over time, leukemic cells lost the unique recipient haplotype while conserving SNP gene copy number through a gain of a second copy of the shared donor haplotype, consistent with the development of aUPD-6p. The non-shared donor haplotype remains present on post-treatment relapse HLA typing due to residual donor cells in the sample. HLA*A is not informative in this case.
which could potentially re-establish morphological remission and increase the likelihood of success of subsequent therapies. This type of intensive treatment approach is often tolerable due to the typically long treatment interval between HSCT and relapse in most patients with aUPD-6p.
All patients in our analyses were in morphologic relapse at the time of aUPD-6p testing, allowing for accurate detection by HLA typing and SNP analysis. More sensitive assays for minimal residual disease detection and additional insights into risk factors for the development of post-HSCT aUPD-6p will help in the formulation of more effective strategies to treat AML relapse. The finding of aUPD in chromosomes other than 6p in the aUPD-6p group suggests that certain AML subtypes may be more prone to this type of mutation, which could be evaluated at the time of presentation to help guide subsequent therapy.
We found that aUPD-6p was a common finding in patients with late relapse of AML after a two-step HI HSCT, and that HLA typing provided a rapid, reliable and inexpensive method for identifying aUPD-6p when sampling was adequate. The finding of clonal evolution of AML, including aUPD-6p, at the time of relapse provides insights into the post-HSCT immunological milieu as well as direction for alternate treatment strategies for relapse.
